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Germline mutations in BRCA1 and BRCA2 cause hereditary breast and ovarian cancer (HBOC). Molecular 15 
screening of these two genes in patients with a family history of breast or ovarian cancer has revealed pathogenic 16 
variants as well as genetic variants of unknown significance (VUS). These VUS may cause a challenge in the 17 
genetic counseling process regarding clinical management of the patient and the family. In this study, we further 18 
characterized 32 variants previously detected in 33 samples from patients with a family history of breast or ovarian 19 
cancer. cDNA was analyzed for alternative transcripts and selected missense variants located in the BRCT domains 20 
of BRCA1 were assessed for their trans-activation ability. 21 
Although an extensive cDNA analysis was done, only three of the 32 variants appeared to affect the splice-process 22 
(BRCA1 c.213-5T>A, BRCA1 c.5434C>G and BRCA2 c.68-7T>A). In addition, two variants located in the BRCT 23 
domains of BRCA1 (c.5075A>C p.Asp1692Ala and c.5513T>G p.Val1838Gly) were shown to abolish the BRCT 24 
domain trans-activation ability, whereas BRCA1 c.5125G>A (p.Gly1709Arg) exhibited equal trans-activation 25 
capability as the WT domain. These functional studies may offer further insights into the pathogenicity of certain 26 
identified variants; however, this assay is only applicable for a subset of missense variants. 27 
 28 
 Key words: BRCA1, BRCA2, cancer, cDNA-analysis, functional-assay 29 




The BRCA1 gene consists of 23 exons and encodes a 208 kDa protein encompassing 1863 amino acids (aa) [1]. 32 
N-terminally, BRCA1 has a RING-domain (aa 8-96) and two nuclear localization signals (aa 200-300) [2]. It also 33 
contains a phosphorylation site for Checkpoint Kinase 2 (CHEK2) protein at Ser988, a coiled coil domain (aa 34 
1364-1437), followed by several phosphorylation sites for Ataxia Telangiectasia Mutated protein (ATM) (between 35 
aa 1280-1524) and two trans-activating BRCT-domains (aa 1646-1859) [2]. BRCA1 has several interactions 36 
partners, for instance BRCA1 associated RING domain 1 (BARD1) protein, which interacts with the RING-37 
domain during homologous recombination repair (HRR) [2]. 38 
The BRCA2 gene consists of 27 exons and encodes a 384 kDa protein encompassing 3418 aa [1]. BRCA2 has 39 
eight BRC-repeats spaced evenly from aa 1009-2083, a helical domain, three oligonucleotide binding folds and a 40 
tower domain [2]. C-terminally, BRCA2 has two nuclear localization signals and a Cyclin Dependent Kinase 2 41 
(CDK2) phosphorylation site at Ser3291 [2].  N-terminally, BRCA2 has the ability to interact with Partner And 42 
Localizer of BRCA2 (PALB2) at aa 21-39, overlapping with exon 3 (aa 23-106) [3]. The physical connection 43 
between BRCA2 and PALB2 is important because PALB2 links BRCA2 and BRCA1 during HRR, at the coiled 44 
coil domain of BRCA1 [2].   45 
Together, mutated BRCA1 and BRCA2 are responsible for about 15-25% of familial breast and ovarian cancer 46 
cases [4, 5]. Pathogenic variants in BRCA1 and BRCA2 are estimated to give a 40-87% risk of breast cancer and a 47 
11-68% risk of ovarian cancer by age 70 [6]. Since the identification of BRCA1 and BRCA2, many pathogenic 48 
variants have been reported in these two genes. The Breast cancer information core (BIC) database includes over 49 
1700 distinct variants in BRCA1 and approximately 2000 in BRCA2 (https://research.nhgri.nih.gov/projects/bic/). 50 
However, many of these variants are classified as variants of unknown significance (VUS) and include 51 
synonymous, missense, intronic and in-frame deletions/insertions. Missense mutations have the capacity to affect 52 
protein function; additionally they may also disturb mRNA splicing. Similarly, synonymous variants, intronic 53 
variants outside the consensus splice sites (ss) and deletions/insertions may also cause aberrant splicing. This has 54 
been reported for several genes including BRCA1 and BRCA2 [7-9]. 55 
Several normal alternative transcripts have been reported both for BRCA1 and BRCA2 [10-13]. The Evidence 56 
based Network for the Interpretation of Germline Mutation Alleles (ENIGMA) consortium reported 63 splicing 57 
events in BRCA1 and 24 in BRCA2 [11, 13]. Ten of the 63 BRCA1 alternative splicing events and four of the 58 
BRCA2 alternative splicing events were considered major splicing events, thus complicating the investigation of 59 
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aberrant splicing [11, 13]. In this study we assessed the consequences of some of the variants detected in a 60 
Norwegian breast and ovarian cancer cohort, both by performing cDNA analysis, as well as evaluating the 61 
functional consequences of  variants located in the BRCA1 C-Terminal (BRCT) domains (aa 1646-1859) using a 62 
trans-activation assay [14, 15]. 63 
Materials and Methods 64 
Patients and samples 65 
Thirty-three whole-blood samples collected in RNA preserving tubes (PAXgene tubes) were obtained from the 66 
University Hospital of Oslo, Norway. The samples were collected from unrelated patients who were carriers of 67 
sequence variants in BRCA1 or BRCA2 (Table 1). All patients had a family history of breast or ovarian cancer. 68 
Complete sequencing of the coding regions, corresponding exon-intron borders and parts of the 5’and 3’ 69 
untranslated regions in BRCA1 and BRCA2 and multiplex ligation-dependent probe amplification (MLPA) were 70 
previously performed for all patients.  In total, these patients carried 18 variants in BRCA1 and 14 variants in 71 
BRCA2 (Table 1). As controls, samples from individuals without a family history of breast- and ovarian cancer 72 
were used.  73 
RNA isolation and cDNA synthesis 74 
RNA was isolated from the PAXgene tubes using the PAXgene Blood RNA Kit (PreAnalytiX, Hombrechtikon, 75 
Switzerland) according to the manufacturer’s protocol. cDNA was synthesized using the SuperScript® VILO™ 76 
cDNA Synthesis Kit (Invitrogen, Waltham, MA USA).  77 
Nomenclature 78 
Variants were named following Human Genome Variation Society (HGVS) nomenclature [16]. Reference 79 
sequences for BRCA1 and BRCA2 were NM_007294.3 and NM_000059.3, respectively. Custom numbering was 80 
used for BRCA1.   81 
Bioinformatic tools 82 
Primers were designed using the Primer 3 software (http://bioinfo.ut.ee/primer3-0.4.0/) [17, 18]. In silico 83 
evaluation of the variants was done with Alamut Visual version 2.7 (Interactive Biosoftware, Rouen, France), 84 
which includes the missense prediction programs Align GVGD, SIFT, MutationTaster and PolyPhen-2. Alamut 85 
also contains the splice prediction tools SpliceSiteFinder-like (SSF), MaxEntScan (MES), NNSPLICE, 86 
GeneSplicer (GS) and Human Splicing Finder (HSF), where the thresholds were set to zero for all prediction tools. 87 
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Alamut also includes results and/or links to the following databases investigated in this study: the Exome 88 
Aggregation Consortium (ExAC), the Exome Variant Server (EVS), the Single Nucleotide Polymorphism 89 
Database (dbSNP), ClinVar, Human Gene Mutation Database (HGMD) and Breast Cancer Information Core 90 
(BIC). 91 
Compliance with Ethical Standards 92 
All participants gave written informed consent for diagnostical testing. The project was submitted to the 93 
appropriate regional ethics committee, however, since the samples were tested with a diagnostically purpose the 94 
regional ethical committee waved the need for ethical approval based on the Norwegian regional health 95 
organization law § 2 and § 9 and the Norwegian research ethical law § 4. 96 
cDNA analysis 97 
The variants were investigated for their effect on splicing. Primers were positioned in flanking exons, preferentially 98 
so PCR-products covered at least one exon on either side of the exon containing the variant of interest (Table 2). 99 
Due to the size of the large exons 11 of BRCA1 and BRCA2, alternative strategies were used. For these exons, the 100 
corresponding PCR-products did not contain the entire exon 11, as one of the primers in each set was located in 101 
exon 11 (Table 2). The PCR-products were visualized on agarose gels, sequenced using Sanger sequencing and 102 
evaluated in Sequencher® version 5.3 (Gene Codes Inc. [19]).  All exonically located variants were used as 103 
markers for biallelic expression. All PCR-reactions were repeated using a second cDNA preparation as template 104 
(prepared from the same RNA sample). 105 
Trans-activation (TA) assay  106 
Plasmids, mutagenesis and transformation. A fusion construct containing GAL4 DBD:BRCA1 (amino acids 107 
1396-1863) WT and the known neutral variant c.4837A>G (p.Ser1613Gly) sub-cloned into pcDNA3 were kindly 108 
provided by Alvaro N.A. Monteiro [15]. As an internal transfection control, the phRG-TK vector was used. The 109 
phRG-TK contains a Renilla-luciferase gene under the control of a constitutive TK-promoter. The pGAL4-e1b-110 
Luc containing the Firefly-luciferase gene was used as a reporter for measuring the trans-activating ability (Figure 111 
2a). Variants c.5075A>C (p.Asp1692Ala), c.5125G>A (p.Gly1709Arg), c.5513T>G (p.Val1838Gly), and the 112 
pathogenic control c.5324T>G (p.Met1775Arg)[15], were introduced in pcDNA3 GAL4 DBD:BRCA1 (amino 113 
acid 1396-1863) WT using the QuikChange XL Site-directed mutagenesis kit (Agilent Technologies, Santa Clara, 114 
CA USA) according to the manufacturer’s protocol. Mutant plasmids were transformed into XL-10 Gold or Top10 115 
competent cells and successful mutagenesis was verified by Sanger sequencing.  116 
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Transfection and harvesting. Both BHK-21 and HEK293 cells (ATCC, www.atcc.org) were grown in 117 
Dulbecco’s Modified Eagle’s Medium (DMEM) (Life Technologies, Waltham, MA USA) with 10% Fetal Bovine 118 
Serum (Life Technologies) and 60 U/ml Penicillin-Streptomycin  (Life Technologies). Approximately 150 000 119 
BHK-21 and 300 000 HEK293 cells were transferred to each well of a 6-well plate and grown overnight before 120 
transfection. One µg of pcDNA3 GAL4 DBD:BRCA1 was co-transfected with one µg of pGAL4-e1b-Luc and 121 
100 ng phRG-TK (internal transfection control). Fugene® HD Transfection Reagent (Promega, Madison, WI 122 
USA) was used as transfecting agent according to the protocol recommended by the supplier. Untransfected cells, 123 
cells transfected exclusively with the reporter plasmids (pGAL4-e1b-Luc and phRG-TK) and cells transfected 124 
with the plasmid containing the BRCA1 WT, the p.Ser1613Gly (neutral) and p.Met1775Arg (pathogenic) variants, 125 
were used as controls. Cells were harvested 24 hours post-transfection. The transfection experiments were repeated 126 
three times. 127 
Luciferase measurements. The Dual-Luciferase Assay System (Promega) was used to measure the trans-128 
activation activity. In short, 50µl Luciferase Assay Reagent II (LARII) was injected into wells containing 20µl 129 
cell lysate. The amount of light produced was measured and subsequently 50µl Stop & Glo Reagent was injected. 130 
A CLARIOstar (BMG LABTECH, Ortenberg, Germany) was used for injections and recordings. For each lysate, 131 
both Renilla- and Firefly-luciferase activities were measured in triplicates. The data are presented as ratios of 132 
Firefly- to Renilla-excitation values. The activity-ratios obtained from cells transfected with only the reporter 133 
plasmid were defined as background and thus subtracted from the activity-ratios obtained from the BRCT 134 
containing plasmids. For each WT lysate/triplicates, the average was calculated. All luciferase measurements 135 
within the same transfection set-up were then calculated as the percentage of the corresponding WT average. 136 
Values were combined, before the average and standard deviations were calculated.  137 
Western blot. Lysates from one of the HEK293 transfections and one of the BHK-21 transfections were used for 138 
western blot analysis to confirm the presence of fusion proteins. The amount of light produced by the internal 139 
transfection control (Renilla luciferase) was used for normalization of samples. Samples were loaded on NuPAGE 140 
4-12% Bis-Tris pre cast gels (Life Technologies) and the proteins were separated for 1.5 hours at 200V and 141 
120mA. Proteins were subsequently transferred to polyvinylidene difluoride (PVDF) membranes (Life 142 
Technologies) (1.5 hours at 25V and 160mA), blocked for one hour in phosphate buffered saline (PBS) with 5% 143 
nonfat dried milk powder (PanReac AppliChem, Darmstadt, Germany) and incubated overnight with 1:200 144 
dilution of BRCA1 (C-20) primary antibodies (Santa Cruz Biotechnology, Dallas, Texas USA). Membranes were 145 
incubated for one hour with HRP-Chicken anti-rabbit secondary antibodies (1:50 000) (Santa Cruz Biotechnology) 146 
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followed by treatment with Signal® West Dura Extended Duration Substrate (Thermo Scientific, Waltham, MA 147 
USA). The ImageQuant Las4000 (GE Healthcare Life Sciences, Buckinghamshire, U.K.) was used to capture 148 
images. 149 
Results  150 
cDNA analysis 151 
Eighteen BRCA1 variants, comprising three intronic and 15 exonic variants, and 14 BRCA2 variants, comprising 152 
one intronic variant and 13 exonic variants were investigated (Table 1 and 3).  All variants, except BRCA1 153 
c.3418A>G and BRCA2 c.4068G>A (which were earlier identified as benign variants [20, 21]), were screened for 154 
their effect on splicing. In addition, all exonic variants (including BRCA1 c.3418A>G and BRCA2 c. 4068G>A) 155 
were used as markers to investigate biallelic expression. 156 
In the performed cDNA analysis, three variants appeared to cause alterations in the normal splicing. BRCA1 c.213-157 
5T>A (intron 5) resulted in inclusion of 59 nucleotides of the 3’-end of intron 5, leading to a frame-shift 158 
introducing an early stop-codon (r.212_213ins213-59_213-1 p.Arg71Serfs*11) (Figure 1a). BRCA1 c.5434C>G 159 
(exon 23) induced skipping of exon 23, also leading to a frame-shift and subsequently an early stop-codon 160 
(r.5407_5467del p.Gly1803Glnfs*11) (Figure 1b). BRCA2 c.68-7T>A (intron 2) appeared to increase skipping of 161 
exon 3 (Figure 1c). Skipping of exon 3 is an in-frame deletion (r.68_316del p.Asp23_Leu105del) which was also 162 
detected in controls. Splice site predictions for these three variants can be seen in Table 4. 163 
Heterozygous positions identified in gDNA that appear homozygous when cDNA is investigated suggest the loss 164 
of expression from one of the alleles or alternative splicing in the investigated region. The majority of patients 165 
with an exonic variant were confirmed to have both alleles transcribed (exception marked in Table 1). 166 
Trans-activation assay 167 
Seven patients were carriers of variants in the BRCT domains of BRCA1 (c.5075A>C, c.5096G>A, c.5117G>C, 168 
c.5123C>T, c.5125G>A, c.5434C>G and c.5513T>G). Of these, three variants were novel (c.5075A>C 169 
p.Asp1692Ala, c.5125G>A p.Gly1709Arg and c.5513T>G p.Val1838Gly). The consequences of these three 170 
variants were further investigated for their trans-activation ability. For the remaining variants c.5434C>G, 171 
c.5096G>A, c.5117G>C and c.5123C>T, we were able to confirm that the sequence variant c.5434C>G caused 172 
aberrant splicing, hence this variant was not included in the TA assay. Variants c.5096G>A (p.Arg1699Gln), 173 
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c.5117G>C (p.Gly1706Ala) and c.5123C>T (p.Ala1708Val) had previously been evaluated by trans-activation 174 
assays and were also not included in the TA assay [22-24].  175 
BRCA1 p.Asp1692Ala and p.Val1838Gly were unable to induce transcription of the firefly luciferase, equal to 176 
the known pathogenic variant p.Met1775Arg, which was apparent in both BHK-21 and HEK293 cells (Figure 2b). 177 
BRCA1 p.Gly1709Arg however, showed trans-activation activity similar to the WT and the known benign variant 178 
p.Ser1613Gly (Figure 2b). 179 
Western blot results indicated an equal expression of the plasmid constructs in the BHK-21 cells, but showed some 180 
variation in HEK293 cells despite adjusting the protein concentrations according to the transfection control, 181 
Renilla luciferase (Figure 2c). However, the BRCT mutants were expressed in both cell types, indicating that the 182 
reduced values were due to reduced trans-activation ability and not due to variations in expression/stability. 183 
Discussion 184 
Prophylactic mastectomy and salphingo-oophorectomy are potent, but invasive risk reducing managements for 185 
carriers of pathogenic BRCA1/2 variants. Accordingly, identifying a VUS pose a considerable challenge for genetic 186 
counsellors and medical geneticists in advising clinical management. In this study, we characterized some of the 187 
variants detected in a Norwegian breast and ovarian cancer cohort, both by cDNA analysis and analysis of the 188 
trans-activation ability of variants located in the BRCT domains. 189 
cDNA analysis 190 
Alternative splicing allows for a more diverse expression of mRNA, and can regulate localization, enzymatic 191 
properties and different interaction properties of proteins [25].  The majority of variants located in the consensus 192 
ss (GT-AG in position +/- 1, 2) lead to abnormal splicing [26], but the effects of variants at positions further away 193 
from the exon-intron border are more difficult to predict. In addition, both missense variants and silent exonic 194 
variants might affect splicing [27], both by creating cryptic ss, remove binding sites for exonic splicing enhancers 195 
(ESE) or create binding sites for exonic splicing silencers (ESS). However, normal alternative splicing can 196 
counteract the effect of some variants leading to aberrant splicing[28]. De La Hoya  et al. (2016) recently reported 197 
a variant leading to BRCA1 Δex10 (out-of-frame), that were rescued by in-frame Δex9,10 [28]. 198 
In the current study, three of the 32 variants had a consequence on pre-mRNA splicing.  199 
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BRCA1 c.213-5T>A, a novel variant located in intron 5, resulted in usage of a cryptic ss 59 nucleotides upstream 200 
of the original site. Three splice prediction tools, SSF, MES and HSF anticipated a 3’ss at the original position. 201 
The variant led to reduced predictions of the original ss (Table 4) and the cryptic ss 59 bases upstream was strongly 202 
predicted by all prediction programs (also in the WT sequence). Inclusion of 59 nucleotides causes a frame-shift, 203 
introducing a premature stop-codon after 75 codons. Another variant in this region, BRCA1 c.213-11T>G, has 204 
previously been shown to lead to the use of the same cryptic ss [8]. The presence of a premature stop-codon likely 205 
activates the nonsense-mediated mRNA decay pathway [29]. However, variants in BRCA1, which introduce a 206 
stop-codon before position c.297, are presumed to allow re-initiation of translation at the AUG at this position 207 
[30]. A re-initiation at c.297 would lead to BRCA1 proteins lacking the RING-finger motif located at the N-termini 208 
(amino acids 8-96)[14]. Binding of the BRCA1 RING-domain to BARD1 protein seems to be essential for tumor 209 
suppression [31], accordingly, variants lacking this domain are expected to be of clinical importance.  210 
BRCA1 c.5434C>G is located in exon 23 and was previously reported by Gaildrat et al. (2010) to cause skipping 211 
of exon 23 [7]. It has been experimentally demonstrated that the variant most likely affects a splice regulatory 212 
element (SRE), either by removal of an ESE or introducing an ESS [7]. This demonstrates  the importance of 213 
experimentally assessing the effect of exonic variants on splicing. BRCA2 c.68-7T>A in intron 2 had previously 214 
been reported by Vreeswijk et. al. (2009) and Sanz et. al. (2010), who performed mini-gene assays that revealed 215 
partial skipping of exon 3 (p.Asp23_Leu105del) [32, 33]. Prediction programs suggested a reduced strength of the 216 
downstream original 3’ss in the presence of the variant (Table 4). The cDNA analysis indicated that the variant 217 
led to increased exon 3 skipping. However, the skipping of exon 3 gives an in-frame alternative transcript, also 218 
present in normal controls (albeit at lower levels). Exon 3 in BRCA2 encodes the part of BRCA2 that interacts with 219 
PALB2 [ 34], however, the consequence (if any) of reduced interaction with PALB2 is currently unknown. Santos 220 
and colleagues have shown that in two families, BRCA2 c.68-7T>A did not segregate with the disease, suggesting 221 
the variant is neutral [35].    222 
Recently, De La Hoya  et al. (2016) [28] suggested that variants in BRCA1 not leading to more than 70-80% loss 223 
of functional transcripts from one of the alleles still can show tumor suppressor haplosufficiency, implicating the 224 
importance of knowing normal alternative splicing events in the genes investigated.  225 
Splice predictions as cDNA analysis inclusion criteria 226 
In 2012, Houdayer et al. introduced specific criteria for selection of variants which should be tested for splicing 227 
[36]. They concluded that as long as the original splice site in BRCA1 or BRCA2 has a prediction value over three 228 
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for the MES prediction tool and over 60 for the SSF prediction tool, a reduction of 15% and 5%, respectively, was 229 
sufficient to include variants for cDNA analysis. Both BRCA1 c.213-5T>A and BRCA2 c.68-7T>A would have 230 
been included using these criteria. However, BRCA1 c.5434C>G would have been omitted from cDNA analysis, 231 
since this variant most likely affects an SRE. Splicing regulatory element predictions were assumed to be unreliable 232 
and therefore not used [36]. In summary, although prediction programs can indicate that some variants can cause 233 
aberrant splicing, the true outcome can only be identified experimentally. 234 
Trans-activation assay 235 
We investigated three novel BRCA1 variants for their effect on BRCA1’s trans-activation activity (Table 1). Two 236 
of the three variants (BRCA1 c.5075A>C p.Asp1692Ala and c.5513T>G p.Val1838Gly) showed a clear loss of 237 
activity (Figure 2b). BRCA1  p.Asp1692Ala exchanging the highly conserved aspartate to an alanine and 238 
BRCA1p.Val1838Gly, substituting the highly conserved valine to a glycine, are both predicted to be pathogenic 239 
by the missense prediction tools Align GVGD, SIFT and mutationTaster. However, PolyPhen-2 only predicts 240 
p.Val1838Gly to be damaging. Both these variants result in changes in the BRCT domains and our functional 241 
study indicated their pathogenicity by loss of trans-activation activity (Figure 2b). Other variants have been 242 
reported at the same positions; p.Asp1692His, p.Asp1692Asn, p.Asp1692Tyr and p.Val1838Glu have all 243 
previously been shown to have a functional impact using the TA-assay, indicating the importance of the conserved 244 
amino acids at these positions [37, 38]. BRCA1 c.5125G>A p.Gly1709Arg however, substituting the highly 245 
conserved glycine with arginine, is predicted differently by Align GVGD, SIFT, Mutation taster and PolyPhen2 246 
(Table 3). Even though some of the prediction programs indicated pathogenicity, p.Gly1709Arg displayed normal 247 
trans-activation activity.  248 
Although the in vitro trans-activation studies suggest the pathogenicity of BRCA1 c.5075A>C and c.5513T>G, we 249 
only investigated a limited part and the BRCA1 protein. Further assessment including segregation studies in 250 
families with these variants are needed to establish their classification. 251 
Several BRCA1 variants in our cohort are classified as either likely pathogenic, likely benign or benign based on 252 
cDNA analysis, functional studies, segregation analysis, frequency in control populations, among others (Table 1 253 
and 3). However, some remain classified as VUS. Two variants identified in our cohort (BRCA1 c.734A>T and 254 
c.1419C>T) have not been previously reported in the literature and both are reported with a low frequency in the 255 
ExAC database [39], accordingly, the clinical significance is uncertain (Table 1). BRCA1 c.3708T>G and 256 
c.5123C>T were previously reported in both the literature and with low frequencies in databases (Table 3).  257 
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In BRCA2 none of the variants identified in our cohort were classified as likely pathogenic. One variant 258 
(c.4068G>A) was classified as benign and five variants (c.750G>A, c.2680 G>A, c.3568C>T, c.6100C>T and 259 
c.6821G>T) were classified as likely benign (Table 1). Eight variants remained classified as VUS; The BRCA2 260 
c.40A>G has not been reported in the investigated databases nor in the literature (Table 3), while the 261 
BRCA2c.8323A>G have not been reported in the literature and only with low frequency in the ExAC database 262 
(Table 3). The five remaining variants, c.4828G>A, c.5272_5274delAAT, c.7301A>C, c.8177A>G and 263 
c.9116C>T, have been reported in the literature, but with low frequencies in the investigated databases (Table 3). 264 
BRCA2 c.8177A>G is however not reported in the ExAC database (Table 3). Our current study was unable to 265 
disclose new variants located in regulatory sequences, affecting the expression of one of the alleles. 266 
Conclusion 267 
In the current study, we identified three variants leading to abnormal splicing of pre-mRNA; Two variants located 268 
intronically, BRCA1 c.213-5T>A and BRCA2 c.68-7T>A and one exonic variant, BRCA1 c.5434C>G. In addition, 269 
functional studies assessing the trans-activation activity of the BRCT domains resulted in identification of two 270 
variants, c.5075A>C p.Asp1692Ala and c.5513T>G p.Val1838Gly, which lacked trans-activation activity. The 271 
use of partial proteins can lead to further understanding of how variants may affect protein function, however, the 272 
use of full-length proteins would be preferable in functional studies. 273 
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Figure and table legends: 454 
Figure 1 cDNA analysis.  At the top of each image the wild type (WT) sequence is shown, followed by the 455 
alternative sequences observed in the patient samples. At the bottom the electropherograms are displayed. (a) 456 
BRCA1 c.213-5T>A resulted in an inclusion of 59 nucleotides from the 3’end of intron 5 (r.212_213ins213-457 
59_213-1 p.Arg71Serfs*11). (b) BRCA1 c.5434C>G resulted in skipping of exon 23 (r.5407_5467del 458 
p.Gly1803Glnfs*11). Electropherogram displayed with sequences from the reverse primer. (c) BRCA2 c.68-7T>A 459 
resulted in increased skipping of exon 3 (r.68_316del p.Asp23_Leu105del), which is a normal alternative splicing 460 
event. 461 
Figure 2 Trans-activation assay. a) A simplified view of the assay set-up; Plasmids with constructs encoding a 462 
DNA binding domain (DBD) and the C-terminal of BRCA1 (amino acids 1396-1863) were co-transfected into 463 
HEK293 and BHK-21 cells with a reporter plasmid containing firefly luciferase. If the plasmids with the C-464 
terminal part of BRCA1 have trans-activation activity, they will activate transcription of firefly luciferase, 465 
luciferase activity is measured and quantitated. b) The dual luciferase reporter assay (Promega) was used to 466 
evaluate the trans-activation activity of BRCA1 BRCT variants in BHK-21 cells and HEK293 cells. The first three 467 
columns represent controls: wild type (WT) BRCA1, a neutral polymorphism (p.Ser1613Gly) and a pathogenic 468 
variant (p.Met1775Arg), respectively.  p.Asp1692Ala (BRCA1 c.5075A>C) and p.Val1838Gly (BRCA1 469 
c.5513T>G) had no trans-activation activity, whereas p.Gly1709Arg (BRCA1 c.5125G>A) showed normal 470 
activity. c) Western blot results from proteins isolated from one of the transfections in BHK-21 cells and HEK293 471 
cells. Samples were normalized according to renilla expression measured by CLARIOstar (BMG 472 
LABTECH).Table 1. The variants/samples investigated in this study. VUS = Variant of unknown clinical 473 
significance. Variants marked in bold have not previously been reported in the literature. 474 
Table 2. List of primers for each sequence variant and the size of the PCR-products without alternative splicing. 475 
Table 3. Predictions, database results and literature for each variant included in the study. Six databases were 476 
explored, the Exome Aggregation Consortium (ExAC), the Exome Variant Server (EVS), the Single Nucleotide 477 
Polymorphism Database (dbSNP), ClinVar, the Human Gene Mutation Database (HGMD) and the Breast Cancer 478 
Information Core (BIC). HD=HumDiv, HV=HumVar, NFE=European (non-Finnish), EA=European American, 479 




Table 4. Splice prediction information for variants with abnormal splicing. Predictions were gathered from the 482 
nearest predicted splice site (ss) change where predictions from several programs (at least two) were made, for 483 
these three variants, only 3’ss were identified. An exception was made for c.213-5T>A, where also the ss at c.213-484 
59 was included in the table. Threshold was set to zero for all four programs. “Pos. ss”= Position of splice site in 485 
regards to sequence variant. Numbers are nucleotides to the splice junction, meaning -0 is right upstream of the 486 
variant, while +0 is right downstream. “NP”=Not predicted, “-“=No change in prediction, “New”=not predicted 487 
in the WT sequence and “Lost”=Not predicted in the variant sequence. 488 
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Figure 2  519 
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Table 1Mutation Location Protein Patient Final Classification 
BRCA1     
c.-20+521_-20+525delAAAAA Intron 1 - 1 2 – likely benign 
c.140G>T Exon 5 p.Cys47Phe 2 4 – likely pathogenic 
c.213-5T>A a Intron 5 - 3 4 – likely pathogenic 
c.486G>T Exon 8 p.= (p.Val162Val) 4 2 – likely benign 
c.548-17G>T Intron 8 - 5 2 – likely benign 
c.734A>T Exon 11 p.Asp245Val 6 3 – VUS 
c.1419C>T Exon 11 p.= (p.Asn473Asn) 7 3 –VUS 
c.1487G>A Exon 11 p.Arg496His 8 2 – likely benign 
c.2521C>T Exon 11 p.Arg841Trp 9 2 – likely benign 
c.3418A>G b Exon 11 p.Ser1140Gly 10 1 – benign 
c.3708T>G Exon 11 p.Asn1236Lys 11 3 – VUS 
c.5075A>C c Exon 18 p.Asp1692Ala 12 3 – VUS 
c.5096G>A Exon 18 p.Arg1699Gln 13 4 – Likely pathogenic 
c.5117G>C Exon 18 p.Gly1706Ala 9 2 – likely benign 
c.5123C>T Exon 18 p.Ala1708Val 14 3 – VUS 
c.5125G>A c Exon 18 p.Gly1709Arg 15 3 – VUS 
c.5434C>G a Exon 23 p.Pro1812Ala 16 4 – likely pathogenic 
c.5513T>G c Exon 24 p.Val1838Gly 17 3 – VUS 
BRCA2     
c.40A>G Exon 2 p.Ile14Val 18 3 – VUS 
c.68-7T>A a Intron 2 - 19 2 – likely benign 
c.750G>A Exon 9 p.= (p.Val250Val) 20, 33 2 – likely benign 
c.2680G>A Exon 11 p.Val894Ile 21 2 – likely benign 
c.3568C>T d Exon 11 p.Arg1190Trp 22 2 – likely benign 
c.4068G>A b,  Exon 11 p.= (p.Leu1356Leu) 23, 10 1 – benign 
c.4828G>A Exon 11 p.Val1610Met 24 3 – VUS 
c.5272_5274delAAT Exon 11 p.Asn1758del 25 3 – VUS 
c.6100C>T Exon 11 p.Arg2034Cys 26 2 – likely benign 
c.6821G>T Exon 11 p.Gly2274Val 27 2 – likely benign 
c.7301A>C Exon 14 p.Lys2434Thr 28 3 – VUS 
c.8177A>G Exon 18 p.Tyr2726Cys 29 3 – VUS 
c.8323A>G Exon 18 p.Met2775Val 30 3 – VUS 
c.9116C>T Exon 23 p.Pro3039Leu 31, 32 3 – VUS 
a Affects pre-mRNA splicing 520 
b Reported homozygote in ExAC 521 
c Part of the BRCT dual luciferase reporter assay 522 




 Mutation Location Forward primer 5’  3’ Reverse primer 5’  3’ Amplicon size (bp) 
BRCA1 c.-20+521_-20+525delAAAAA Intron 1 BRCA1 ex1.F CTCGCTGAGACTTCCTGGAC  BRCA1 ex3.R TGTGGAGACAGGTTCCTTGA 227 
c.140G>T Exon 5 BRCA1 ex2.F GCTCTTCGCGTTGAAGAAGT  BRCA1 ex7.R GAAGTCTTTTGGCACGGTTT 400 
c.213-5T>A Intron 5 BRCA1 ex2.F GCTCTTCGCGTTGAAGAAGT  BRCA1 ex7.R GAAGTCTTTTGGCACGGTTT 400 
c.486G>T Exon 8 BRCA1 ex6.F CAGCTTGACACAGGTTTGGA BRCA1 ex11a.R TTTCTGGATGCCTCTCAGCT 499 
c.548-17G>T Intron 8 BRCA1 ex6.F CAGCTTGACACAGGTTTGGA BRCA1 ex11a.R TTTCTGGATGCCTCTCAGCT 499 
c.734A>T Exon 11 BRCA1 ex8.F GAGGACAAAGCAGCGGATAC BRCA1 ex11.1R GCTGTAATGAGCTGGCATGA  359 
c.1419C>T Exon 11 BRCA1 ex8.F GAGGACAAAGCAGCGGATAC BRCA1 ex11.2R CCGTTTGGTTAGTTCCCTGA 1,124 
c.1487G>A Exon 11 BRCA1 ex8.F GAGGACAAAGCAGCGGATAC BRCA1 ex11.2R CCGTTTGGTTAGTTCCCTGA 1,124 
c.2521C>T Exon 11 BRCA1 ex11.F CAGCATTTGAAAACCCCAAG BRCA1 ex13.R ATGGAAGGGTAGCTGTTAGAAGG 1,879 
c.3418A>G Exon 11 BRCA1 ex11.1F TAGGGGTTTTGCAACCTGAG BRCA1 ex13.R ATGGAAGGGTAGCTGTTAGAAGG 1,039 
c.3708T>G Exon 11 BRCA1 ex11.1F TAGGGGTTTTGCAACCTGAG BRCA1 ex13.R ATGGAAGGGTAGCTGTTAGAAGG 1,039 
c.5075A>C Exon 18 BRCA1 ex16.F GGGAGAAGCCAGAATTGACA  BRCA1 ex20.R CTCGCTTTGGACCTTGGTG 354 
c.5096G>A Exon 18 BRCA1 ex16.F GGGAGAAGCCAGAATTGACA  BRCA1 ex20.R CTCGCTTTGGACCTTGGTG 354 
c.5117G>C Exon 18 BRCA1 ex16.F GGGAGAAGCCAGAATTGACA  BRCA1 ex20.R CTCGCTTTGGACCTTGGTG 354 
c.5123C>T Exon 18 BRCA1 ex16.F GGGAGAAGCCAGAATTGACA  BRCA1 ex20.R CTCGCTTTGGACCTTGGTG 354 
c.5125G>A Exon 18 BRCA1 ex16.F GGGAGAAGCCAGAATTGACA  BRCA1 ex20.R CTCGCTTTGGACCTTGGTG 354 
c.5434C>G Exon 23 BRCA1 ex21.F TTCAGGGGGCTAGAAATCTG  BRCA1 ex24.R AAGCTCATTCTTGGGGTCCT 289 
c.5513T>G Exon 24 BRCA1 ex21.F TTCAGGGGGCTAGAAATCTG  BRCA1 ex24.R GGGGTATCAGGTAGGTGTCC 289 
BRCA2 c.40A>G Exon 2 BRCA2 ex1.F AGCGTGAGGGGACAGATTTG BRCA2 ex4.R GTGGACAGGAAACATCATCTGC 519 
c.68-7T>A Intron 2 BRCA2 ex1.F AGCGTGAGGGGACAGATTTG BRCA2 ex4.R GTGGACAGGAAACATCATCTGC 519 
c.750G>A Exon 9 BRCA2 ex7.F AGGAGCTGAGGTGGATCCTG  BRCA2 ex11.R1 TCAGAATTGTCCCAAAAGAGCT 1,451 
c.2680G>A Exon 11 BRCA2 ex10.F GTTCAGCCCAGTTTGAAGCA BRCA2 ex11.R2 TGACACTTGGGTTGCTTGTT 980 
c.3568C>T Exon 11 BRCA2 ex10.F GTTCAGCCCAGTTTGAAGCA BRCA2 ex11.R3 CTTGAGCTTTCGCAACTTCC 2,343 
c.4068G>A Exon 11 BRCA2 ex10.F GTTCAGCCCAGTTTGAAGCA BRCA2 ex11.R3 CTTGAGCTTTCGCAACTTCC 2,343 
c.4828G>A Exon 11 BRCA2 ex11.F1 CAATGGGCAAAGACCCTAAA  BRCA2 ex13.R CGAAAGGGTACACAGGTAATCG 2,324 
c.5272_5274delAAT Exon 11 BRCA2 ex11.F2 TTTGATGGTCAACCAGAAAGAA BRCA2 ex13.R CGAAAGGGTACACAGGTAATCG 1,916 
c.6100C>T Exon 11 BRCA2 ex11.F3 CGCAAGACAAGTGTTTTCTGA  BRCA2 ex13.R CGAAAGGGTACACAGGTAATCG 1,023 
c.6821G>T Exon 11 BRCA2 ex11.F3 CGCAAGACAAGTGTTTTCTGA  BRCA2 ex13.R CGAAAGGGTACACAGGTAATCG 1,023 
c.7301A>C Exon 14 BRCA2 ex11.F4 TGTCCCGAAAATGAGGAAATGG BRCA2 ex16.R TGTGAAACTGAAAAGACTCTGCA 925 
c.8177A>G Exon 18 BRCA2 ex16.F GGTGGATGGCTCATACCCTC BRCA2 ex20.R TTTGCTGCTTCCTTTTCTTCC 809 
c.8323A>G Exon 18 BRCA2 ex16.F GGTGGATGGCTCATACCCTC BRCA2 ex20.R TTTGCTGCTTCCTTTTCTTCC 809 






Mutation Location Protein Prediction programs Databases Ref. 
Align 
GVGD  
SIFT  Mutation taster  PolyPhen2  ExAC ESP/EVS dbSNP ClinVar HGMD BIC 
BRCA1 




Intron 1 -  - - - - - - -  - - - - 
c.140G>T Exon 5 p.Cys47Phe C65  Deleterious Disease causing  HD: POSSIBLY 
DAMAGING  
HV: BENIGN 








c.213-5T>A Intron 5 -  - - - - - - -  - - - - 
c.486G>T Exon 8 p.= (p.Val162Val)  - - - - - - -  - - - - 
c.548-17G>T Intron 8 -  - - - - ALL:T=0.017%N
FE:0.023% 



















c.1419C>T Exon 11 p.= 
(p.Asn473Asn) 
 - - - - ALL:T=0.0025% 
NFE:0.0045% 
- - RCV000165155.1 - - - 
































































c.5075A>C Exon 18 p.Asp1692Ala  C65 Deleterious Disease causing HD: BENIGN  
HV: BENIGN 
- - -  - - - - 


















































- [24, 52] 
c.5125G>A Exon 18 p.Gly1709Arg  C15  Deleterious Disease causing HD: POSSIBLY 
DAMAGING 
HV: BENIGN 
- - - - - - - 
c.5434C>G Exon 23 p.Pro1812Ala  C0 Tolerated Disease causing HD: BENIGN  
HV: BENIGN 












- - - - - - - 
BRCA2 
             
c.40A>G Exon 2 p.Ile14Val  C0 Tolerated Polymorphism HD: BENIGN  
HV: BENIGN 
- - -  - - - - 
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c.4068G>A Exon 11 p.= 
(p.Leu1356Leu) 



























Exon 11 p.Asn1758del  - - - - ALL:0.0050% 
NFE:0.0091% 
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SSF [0-100] MES [0-16] NNSPLICE [0-1] GS [0-15] HSF [0-100] 
BRCA1 c.213-5T>A Intron 5 3 +4 -7.6% -52.1% Lost 0.1 NP -4.0% 
   -54 - - - +3.3% - 
BRCA1 c.5434C>G Exon 23 16 -0 / +7.1% +20.9% New 0.6 -  +5.2%  
   +3 NP 200% NP NP 0.7% 
BRCA2 c.68-7T>A Intron 2 19 +6 -5.7% -23.9 % -27.3% - -2.7% 
 
